X

BIOLASE, Inc. (BIOL) Sells Last of WaterLase MD Turbo Laser Systems Repurchased from Schein

Leading global dental laser manufacturer and distributor BIOLASE announced that it has sold the last of 159 WaterLase MD Turbo laser systems the company repurchased from Henry Schein earlier this year.

BIOLASE originally intended to use a portion of the purchased Schein inventory for parts to service its large installed base of MD Turbo laser systems. Due to high demand for the equipment, however, the company ultimately elected to sell all of the repurchased laser systems. Under a February 2012 agreement, BIOLASE repurchased the units from Schein at a very advantageous price, selling them throughout the last three quarters at margins consistent with the company’s other laser products.

Both the effectiveness and the benefits of having a wide range of WaterLase products have been demonstrated by the strong demand for these WaterLase MD Turbo laser systems over the past three quarters, as well as by a period of consistent growth in the direct sales of BIOLASE’s flagship WaterLase iPlus.

A biomedical company, BIOLASE is engaged in developing, manufacturing, and marketing dental lasers; the company additionally distributes and markets dental imaging equipment and products that are focused on technologies to advance the practice of dentistry and medicine. BIOLASE’s laser products incorporate around 290 patented and patent-pending technologies that are designed to provide biological treatment and clinically superior performance with decreased pain and accelerated recovery times. The company’s imaging products offer cutting-edge technology at competitive prices, providing dentists and patients with the best results. BIOLASE’s chief products are dental laser systems that perform a wide range of dental procedures – including cosmetic and complex surgical applications – and a complete line of dental imaging equipment and CAD/CAM systems. The company has sold more than 21,000 lasers, and other BIOLASE products are under development to address ophthalmology and other medical and consumer markets.

For more information, visit www.biolase.com

Let us hear your thoughts below:

Related Post